ArticleHelminthologia2018
β-Glucan and Parasites.
Article in Helminthologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Therapeutic potential of oral alginate nanoparticles against experimental toxoplasmosis.Parasitology research · 2024Article
- β-1,3-Glucan recognition byApplied and environmental microbiology · 2024Article
- β-Glucan alleviates goal-directed behavioral deficits in mice infected with Toxoplasma gondii.Parasites & vectors · 2023Article
- A new insight in immunomodulatory impact of botanicals in treating avian coccidiosis.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2022Review
- Trained Immunity as an Adaptive Branch of Innate Immunity.International journal of molecular sciences · 2021Review
- Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity.Microorganisms · 2021Review
- Effects of Prebiotics and Probiotics on Honey Bees (Microorganisms · 2021Article
- The Herbal Supplements NOZEMAT HERBPathogens (Basel, Switzerland) · 2021Article
- Hypolipidemic Effects of β-Glucans, Mannans, and Fucoidans: Mechanism of Action and Their Prospects for Clinical Application.Molecules (Basel, Switzerland) · 2020Review
- Efficient Control of IL-6, CRP and Ferritin in COVID-19 Patients With Two Variants of Beta-1,3-1,6 Glucans in Combination: An Open-Label, Prospective, Randomised Clinical Trial.Global advances in integrative medicine and healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunosuppression caused by parasitic infections represents the foremost way by which the parasites overcome or escape the host's immune response. Glucan is a well-established natural immunomodulator with the ability to significantly improve immune system, from innate immunity to both branches of specific immunity. Our review is focused on the possible role of glucan's action in antiparasite therapies and vaccine strategies. We concluded that the established action of glucan opens a new window in treatment and protection against parasitic infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.